SciELO - Scientific Electronic Library Online

 
vol.11 issue1Bioethical problems in researching new vaccines: Do they respond to public health reasons?Antipsychotics for schizophrenia: the paradigm of psychiatric drugs author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

  • Have no cited articlesCited by SciELO

Related links

  • Have no similar articlesSimilars in SciELO

Share


Salud colectiva

On-line version ISSN 1851-8265

Abstract

RUBENICH, Gustavo Butzge; HECK, Stephanie Tomasi; HELLMANN, Fernando  and  SCHLEMPER JUNIOR, Bruno Rodolfo. The use of placebos in phase III clinical trials in Brazil. Salud colect. [online]. 2015, vol.11, n.1, pp.99-114. ISSN 1851-8265.

In 2008, Brazil's Federal Council of Medicine [Conselho Federal de Medicina] (CFM) - regulatory and supervisory agency on the ethical practice of medicine - banned the participation of Brazilian doctors in studies using placebos for diseases with efficient and effective treatment. This position differs with the Helsinki Declaration, which allows the use of placebos in methodologically justified conditions. To ascertain whether the CMF's ethical regulation modified the use of placebos in phase III clinical trials in Brazil, characteristics of the records in ClinicalTrials.gov were researched in the periods from 2003 to 2007 and from 2009 to 2013. The conclusions reached were: a) the regulations issued by the CFM in 2008 were ineffective and the position adopted by the Helsinki Declaration prevails; b) there was significant sponsorship by the multinational pharmaceutical industry of trials with placebos; c) the research was predominantly on new drugs for chronic diseases, with little study done of the neglected diseases which are of great importance to Brazil.

Keywords : Ethics, Research; Ethics, Medical; Clinical Trial; Placebos; Helsinki Declaration.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License